Dr Carol De Santis - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.

aProximateTM

Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

Dr Carol De Santis

Scientist, In-vitro Toxicology

Carol joined Newcells as an in-vitro toxicology specialist. She oversees toxicology assay development and model characterisation for R&D and commercial services, and currently focuses on the development of high-throughput multiplex assays to investigate retinal toxicity.

Carol gained her PhD in Toxicology and Drug Safety following an MRC Integrative Toxicology training partnership between Newcastle University, the University of Liverpool and UCB Pharma (Belgium), where she gained experience in preclinical investigative toxicology, and characterised several in-vitro models for drug discovery applications. During her studies she has won numerous awards, including an In-Vitro Toxicology Society Early Career Scientist Prize in 2017. Prior to her PhD, Carol worked in the Biotech industry in Germany, and pursued a Master of Research in Toxicology in the UK. She has been an active member of the British Toxicology Society for several years.

Originally half Italian and half Czech, Carol fluently speaks four languages, and has gained international work experience in many places in Europe including the UK, Belgium, Germany and the Czech Republic. When she is not busy with work, Carol enjoys beach walks, travelling and winter sports.

Favourite quotation “The way to get started is to quit talking and begin doing” Walt Disney